These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25952203)

  • 1. Invited commentary.
    Antonoff MB
    Ann Thorac Surg; 2015 May; 99(5):1754. PubMed ID: 25952203
    [No Abstract]   [Full Text] [Related]  

  • 2. Methylated DLX4 Predicts Response to Pathologic Stage I Non-Small Cell Lung Cancer Resection.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Ohdan H; Okada M
    Ann Thorac Surg; 2015 May; 99(5):1746-54. PubMed ID: 25825198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
    Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
    Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invited commentary.
    Lee HS; Zo JI
    Ann Thorac Surg; 2012 May; 93(5):1613. PubMed ID: 22541191
    [No Abstract]   [Full Text] [Related]  

  • 5. Invited commentary.
    Antonoff MB
    Ann Thorac Surg; 2013 Sep; 96(3):968. PubMed ID: 23992693
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of BP1 mRNA expression level in patients with non-small cell lung cancer.
    Yu M; Wan Y; Zou Q
    Clin Biochem; 2008 Jul; 41(10-11):824-30. PubMed ID: 18420035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invited commentary.
    Antonoff M
    Ann Thorac Surg; 2015 Apr; 99(4):1148. PubMed ID: 25841807
    [No Abstract]   [Full Text] [Related]  

  • 9. One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer.
    Neal JW; Shaw AT
    Clin Cancer Res; 2011 Feb; 17(4):638-9. PubMed ID: 21163872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IRX1 hypomethylation in osteosarcoma metastasis.
    Lu J; Wang J
    Oncotarget; 2015 Jul; 6(19):16802-3. PubMed ID: 26158902
    [No Abstract]   [Full Text] [Related]  

  • 11. Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis.
    Ren M; Wang C; Sheng D; Shi Y; Jin M; Xu S
    Ann Diagn Pathol; 2017 Apr; 27():57-61. PubMed ID: 28325362
    [No Abstract]   [Full Text] [Related]  

  • 12. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
    Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
    Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
    Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
    J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.
    Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D
    J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic immune markers in non-small cell lung cancer--letter.
    Pandey JP
    Clin Cancer Res; 2011 Dec; 17(24):7835; author reply 7836. PubMed ID: 22147937
    [No Abstract]   [Full Text] [Related]  

  • 16. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
    Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
    Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy.
    Bortolin MT; Tedeschi R; Bidoli E; Furlan C; Basaglia G; Minatel E; Gobitti C; Franchin G; Trovò M; De Paoli P
    Biomarkers; 2015; 20(6-7):422-8. PubMed ID: 26526078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.
    Walter RFH; Rozynek P; Casjens S; Werner R; Mairinger FD; Speel EJM; Zur Hausen A; Meier S; Wohlschlaeger J; Theegarten D; Behrens T; Schmid KW; Brüning T; Johnen G
    PLoS One; 2018; 13(5):e0195716. PubMed ID: 29851970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer.
    He B; You L; Xu Z; Mazieres J; Lee AY; Jablons DM
    Clin Lung Cancer; 2004 May; 5(6):366-70. PubMed ID: 15217536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy.
    Pernía O; Belda-Iniesta C; Pulido V; Cortes-Sempere M; Rodriguez C; Vera O; Soto J; Jiménez J; Taus A; Rojo F; Arriola E; Rovira A; Albanell J; Macías MT; de Castro J; Perona R; Ibañez de Caceres I
    Epigenetics; 2014 Nov; 9(11):1446-53. PubMed ID: 25482372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.